Purple Biotech 在 2025 年 9 月的更新中公布了有前景的癌症治疗进展
Purple Biotech (PPBT) announced advancements in oncology therapies on September 15, 2025, highlighting two first-in-class drugs in Phase 2 trials, CM24 and NT219. The company has a cash balance of $10.5 million, ensuring financial stability into the first half of 2027. Analyst ratings are mixed, with a Buy rating and a $34.00 price target, while Spark's AI Analyst rates it as Underperform due to financial challenges and unattractive valuation metrics. Purple Biotech focuses on developing innovative cancer treatments with high unmet medical needs.
Purple Biotech ( (PPBT) ) has issued an update.
On September 15, 2025, Purple Biotech Ltd. released an updated corporate presentation highlighting its advancements in oncology therapies. The company is progressing with two first-in-class drugs in Phase 2 trials, CM24 and NT219, which show promising results in personalized immunotherapy and tumor sensitization. With a cash balance of $10.5 million as of September 10, 2025, Purple Biotech has a financial runway into the first half of 2027, indicating a stable financial position to continue its innovative cancer treatment developments.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech is a pharmaceutical company focused on developing first-in-class drug candidates for treating cancers with high unmet medical needs. The company is working on next-generation tri-specific antibody platforms, including CAPTN-3, which is designed to enhance T-cell and NK cell engagement.
Average Trading Volume: 1,009,903
Technical Sentiment Signal: Sell
Current Market Cap: $5.39M
